UCB adds to CNS portfolio with acquisition of Lectus' key pharmaceutical assets

23 November 2011

Belgian drugmaker UCB (Euronext Brussels: UCB) has acquired the key pharmaceutical assets of closely-held, UK based drug developer Lectus Therapeutics via a licence and acquisition agreement.

Lectus is focusing on next-generation ion channel modulators. The transaction involves the acquisition of all the company’s drug discovery and development programs targeting ion channels for the treatment of a specific set of central nervous system (CNS) indications. Financial details of the deal were not disclosed.

Under the terms of the agreement UCB will also gain exclusive worldwide rights to commercialise products discovered from the use of Lectus’ proprietary LEPTICS technology for a number of further ion channel targets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK